Yaokang Biotechnology (688046.SH): Spent a total of 23.86 million yuan to repurchase 0.3712% of shares.

On July 1st, Gelunhui announced that, by June 30th, 2024, the company had repurchased a total of 1,521,975 shares through the centralized bidding trading method on the Shanghai Stock Exchange, accounting for 0.3712% of the total share capital of 410,000,000 shares. The highest repurchase price was 19.17 yuan/share and the lowest was 11.89 yuan/share, with a total payment of 23,862,462.57 yuan (excluding stamp duty, transaction commission and other transaction fees).

Gelonghui FinanceJul 1 04:25 ET

Is GemPharmatech (SHSE:688046) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor

Simply Wall StJun 19 18:16 ET

Yaokang Biotechnology (688046.SH): Currently, the old production capacity is fully utilized, and new production capacity is gradually being added according to production plans.

PharmaKang Biological (688046.SH) stated on the investor interaction platform on June 18th that the company operates seven large-scale production facilities in Nanjing, Jiangsu, Changzhou, Jiangsu, Foshan, Guangdong, Chengdu, Sichuan, Daxing, Beijing, and Baoshan, Shanghai, with a total capacity of approximately 280,000 cages, of which 80,000 cages are newly added capacity in 2023. Currently, the old capacity is at full production, and the new capacity is climbing according to the production plan.

Gelonghui FinanceJun 18 04:01 ET

Yaokang Biotechnology (688046.SH): Qingdao National Medicine plans to reduce its shareholding by no more than 1.5%.

PharmaKang Biological (688046.SH) announced on June 7 that, due to its own funding needs, Qingdao Guoyao intends to reduce its shareholding in the company through block trading, with a total reduction of no more than 6,150,000 shares, or 1.50% of the total share capital of the company. The reduction will be carried out within three months after 15 trading days from the date of this announcement.

Gelonghui FinanceJun 7 04:27 ET

The major shareholder of Pharmaron Biological (688046.SH), Qingdao State Pharmaceutical Co., Ltd., plans to reduce its shareholding by no more than 1.5%.

Pharmaron Biotech (688046.SH) announced that Qingdao National Medicine Venture Capital Investment Partnership (...) holds more than 5% of the company's shares.

Zhitong FinanceJun 7 04:26 ET

Yakkang Biotech (688046.SH): A total cost of 238.625 million yuan to buy back 0.3712% of shares

Gelonghui, May 31, 丨 Yakang Biotech (688046.SH) announced that as of May 31, 2024, the company had repurchased a total of 1,521,975 shares through the Shanghai Stock Exchange trading system, accounting for 0.3712% of the company's total share capital of 410,000,000 shares. The highest price of the repurchase transaction was 19.17 yuan/share, the lowest price was 11.89 yuan/share, and the total amount of capital paid was RMB 23,862,462.57 (excluding transaction fees such as stamp duty and transaction fees).

Gelonghui FinanceMay 31 04:29 ET